The Immune-Image consortium covers all relevant elements of the value chain of immunotracer development. Our consortium has the expertise and capabilities to design, synthesize, evaluate and validate new immunotracers in a strongly translational and reverse-translational manner: from bench to bedside and back.
Immune-Image consists of 21 key stakeholders from across 9 countries, bringing together their extensive expertise, infrastructure and stakeholders.
10
academic and medical institutions
7
pharmaceutical companies (EFPIA)
4
SMEs
PARTNERS
Coordinator
Leader
GOVERNANCE
The governance structure of Immune-Image on a strategic level involves a General Assembly, Management Board, Workpackages leaders.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 831514. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
